BioSpace News Archive

As previously announced, APTI’s scientists identified multiple compounds with high predicted affinity for the main SARS-CoV-2 protease by in silico modeling and synthetic efforts and preliminary testing were initiated.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that it has entered into an option agreement (“Option”) with The Texas A&M University System (“TAMUS”) for exclusive rights to the intellectual property covering highly potent main protease (MPro) inhibitors against SARS-CoV-2.

Researchers at Albert Einstein College of Medicine and the City University of New York Graduate School of Public Health and Health Policy (CUNY SPH) have been awarded a five-year, $14.5 million grant from the National Institutes of Health (NIH)

Next Science Limited (ASX:NXS), an innovative medical technology company, announced that it will exhibit at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting and conference in San Diego, California, from Aug. 31 – Sept. 3.

Imbed Biosciences announced today that it has signed a distribution agreement with Spartan Medical.

A new study by scientists at Gladstone Institutes led by Senior Investigator Katerina Akassoglou, PhD, shows that many of the drugs currently in trials may not be sufficient to promote repair within these cells’ toxic environment and identifies a different treatment option that could improve the repair of myelin.

Q-State Biosciences (“Q-State”), a discovery technology and therapeutics company advancing programs for the treatment of epilepsy, pain, and other disorders of the central nervous system, today announced that Chief Scientific Officer, Graham Dempsey, PhD, will be giving an oral presentation at the upcoming 2021 World Orphan Drug Congress USA

Aatru Medical, LLC (“Aatru”) today announced U.S. Food and Drug Administration (FDA) 510(k) Class II clearance of the NPSIMS™ Negative Pressure Surgical Incision Management System.

FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the “Company” or “FSD”) announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide (“PEA”), or FSD-201, for use in treating COVID-19.

Pharmapack 2021 will showcase many of the latest innovations in the industry and bring the entire community together to help foster new advances.